PEMIGATINIB for Neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 5 adverse event reports in the FDA FAERS database where PEMIGATINIB was used for Neoplasm malignant.
Most Reported Side Effects for PEMIGATINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Off label use | 114 | 16.1% | 28 | 19 |
| Disease progression | 103 | 14.5% | 38 | 13 |
| Death | 76 | 10.7% | 76 | 6 |
| Fatigue | 72 | 10.2% | 5 | 7 |
| Alopecia | 53 | 7.5% | 2 | 5 |
| Hyperphosphataemia | 46 | 6.5% | 10 | 11 |
| Cholangiocarcinoma | 44 | 6.2% | 19 | 4 |
| Diarrhoea | 42 | 5.9% | 0 | 10 |
| Constipation | 37 | 5.2% | 2 | 4 |
| Drug ineffective | 37 | 5.2% | 13 | 3 |
| Hospitalisation | 35 | 4.9% | 0 | 34 |
| Nausea | 35 | 4.9% | 5 | 5 |
| Decreased appetite | 34 | 4.8% | 3 | 5 |
| Stomatitis | 31 | 4.4% | 2 | 6 |
| Dry mouth | 30 | 4.2% | 1 | 2 |
Other Indications for PEMIGATINIB
Cholangiocarcinoma (431)
Bile duct cancer (34)
Glioblastoma (12)
Adenocarcinoma of salivary gland (10)
Pancreatic carcinoma (8)
Malignant lymphoid neoplasm (7)
Bladder cancer (6)
Hepatic cancer (5)
Myeloproliferative neoplasm (5)
Other Drugs Used for Neoplasm malignant
PALBOCICLIB (1,996)
CAPECITABINE (1,493)
PEMBROLIZUMAB (1,135)
PACLITAXEL (984)
CARBOPLATIN (977)
NIVOLUMAB (947)
OXALIPLATIN (823)
PAZOPANIB (716)
CYCLOPHOSPHAMIDE (685)
FLUOROURACIL (676)